ESR1 and breast carcinoma: This may be seen as a disadvantage associated with the utilization of Luminal B breast cancer cell line types, as the more invasive characteristics weaken the luminal phenotype that is associated with high expression of HER2+ expression which, in turn, downregulates the expression of ER+ [16].